Prot #FRF4998g: An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients with Relapsed or Refractory Multiple Myeloma.

Project: Research project

Project Details

StatusFinished
Effective start/end date1/13/12 → 1/13/18

Funding

  • Genentech, Inc. (Prot #FRF4998g)